Globalpharma signs marketing and distribution agreement with international pharmaceutical giant Ethypharm
Globalpharma, a subsidiary of Dubai Investments PJSC, has signed a major contract with Ethypharm India, a subsidiary of leading French multinational drug delivery company Ethypharm S.A., to secure the marketing and distribution rights for five new products in different therapeutic segments. The agreement follows a similar deal that Ethypharm signed with Globalpharma for out-licensing of Cetirizine 10 mg Oro-dispersible tablets last year.
Under the terms of the agreement, Ethypharm India will be responsible for the development and supply of the five products, whereas Globalpharma will be responsible for manufacturing, marketing and distribution of the products in the Middle East and Gulf markets.
The products include (Emidol) Paracetamol 500mg Flashtab® (Analgesic Antipyretic); (Emicipro) Ciprofloxacin Sustained Release 1000mg (Antibiotic); (Emiphage) Metformin Sustained Release 1000mg (Antidiabetic); (Emicron) Gliclazide Sustained Release 30mg (Antidiabetic); and Pseudoephedrine Sustained Release 120mg & Cetirizine 5 mg in combination (Antiallergic).
“This agreement strengthens our partnership with Ethypharm and further expands our burgeoning product portfolio,” said Dr. Maged Amer, General Manager, Globalpharma. “Globalpharma is focused on bringing quality pharmaceutical products from globally reputed companies to the Middle East market, and the new marketing and distribution contract with Ethypharm is in line with our corporate objectives. We are certain this move will serve to reinforce our market standing.”
Ajey Kumar, Chief Executive Officer of Ethypharm India, said, “We are delighted to take our alliance with Globalpharma to the next level. With this deal, Ethypharm has clearly established a leadership position in the drug delivery segment of Middle East and Gulf region.”
Established in 1998 as a subsidiary of Dubai Investments, Globalpharma manufactures pharmaceutical products under CGMP condition including antibiotics, cardiovascular, anti-ulcerants, analgesic NSAIDs, food supplements, vitamins, anti-diabetics, respiratory products and anti-histamine formulations, in addition to marketing and distributing products of multinational pharmaceutical companies.
Ethypharm pharmaceutical company focuses on developing, manufacturing and licensing pharmaceutical products based on optimization of delivery through proprietary technologies, mainly in the oral sustained release formulations. The company has a special focus on pain management, cardiovascular, oncology and CNS branded and generic products. Over the years, Ethypharm has developed more than 50 branded and generic products, based on its core proprietary technologies. Ethypharm is a French company, present on the principal world health markets with manufacturing and R & D sites in Europe, in North America, China and India. Ethypharm India is a 100% subsidiary of Ethypharm S.A., France.
- World's leading pharmaceutical company wins joint Saudi contract
- Abbott Laboratories to launch new drug at Arab Health Exhibition
- India’s Dabur anti-cancer drug to be manufactured in Iran
- Oman Pharmaceutical Products Company opens for business
- Gulf investor seeks stake in Egypt’s CID pharmaceutical company